All lobbying filings

ACCENDRA HEALTH INC.

Lobbying for ACCENDRA HEALTH INC.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Virginia · House · Senate · $250,000.00 expenses · posted Jul 13, 2026

Official filing document

Bills named in this filing 6

S 4037
Diabetes Act
HR 2005
DMEPOS Relief Act of 2025
S 2951
Competitive Bidding Relief Act
HR 2902
SOAR Act of 2025
S 1406
SOAR Act of 2025
HR 8871
DME Scammer Prevention Act of 2026

Lobbying activity 3

Health Issues

Issues related to patient access to home medical equipment and related reimbursement.

Medicare/Medicaid

Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.

Budget/Appropriations

FY 2027 Appropriations.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.